F1I
AVBP icon

Fund 1 Investments’s ArriVent BioPharma AVBP Stock Holding History

Fund 1 Investments’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Sell
499,990
-65,861
-12% -$1.49M 1.32% 22
2025
Q4 		$11.4M Sell
565,851
-54,000
-9% -$1.12M 1.39% 17
2025
Q3 		$11.4M Buy
619,851
+91,456
+17% +$1.8M 1.27% 22
2025
Q2 		$11.5M Buy
+528,395
New +$11M 0.93% 25

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fund 1 Investments's AVBP Position: Q1 2026 in Review

Fund 1 Investments reduced its ArriVent BioPharma (AVBP) stake by 12% in Q1 2026, selling an estimated $1.49M and leaving 499,990 shares worth $11.5M. The position accounts for 1.32% of the portfolio, ranked #22.

Fund 1 Investments first reported a position in AVBP in Q2 2025 and has held it in 4 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Fund 1 Investments held 499,990 shares of ArriVent BioPharma worth $11.5M as of Q1 2026.
  • Fund 1 Investments sold 65,861 ArriVent BioPharma shares in Q1 2026, an estimated $1.49M.
  • ArriVent BioPharma made up 1.32% of Fund 1 Investments's portfolio in Q1 2026, its #22 holding.
  • Fund 1 Investments first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 4 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Fund 1 Investments's 13F filing for Q1 2026, filed 15 May 2026.